文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

长达10年的针对中东呼吸综合征冠状病毒（MERS-CoV）的细胞免疫和体液免疫可交叉识别严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的野生型和变体：MERS-CoV对泛冠状病毒疫苗的一种潜在单向交叉保护作用。

A 10 Year Long-Lived Cellular and Humoral MERS-CoV Immunity Cross-Recognizing the Wild-Type and Variants of SARS-CoV-2: A Potential One-Way MERS-CoV Cross-Protection Toward a Pan-Coronavirus Vaccine.

作者信息

Alosaimi Bandar, Awadalla Maaweya, Alturaiki Wael, Chen Zhao, Zhang Zhaoyong, Zhu Airu, Rebh Fatimah, Alshukairi Abeer N, Zhao Jincun, Alkadi Haitham S

机构信息

Research Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.

Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah, Riyadh Region, Saudi Arabia.

出版信息

J Med Virol. 2025 Jan;97(1):e70071. doi: 10.1002/jmv.70071.

DOI:10.1002/jmv.70071
PMID:39822038
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11740004/
Abstract

MERS is a respiratory disease caused by MERS-CoV. Multiple outbreaks have been reported, and the virus co-circulates with SARS-CoV-2. The long-term (> 6 years) cellular and humoral immune responses to MERS-CoV and their potential cross-reactivity to SARS-CoV-2 and its variants are unknown. We comprehensively investigated long-lasting MERS-CoV-specific cellular and humoral immunity, and its cross-reactivity against SARS-CoV-2 and its variants, in individuals recovered from MERS-CoV infection 1-10 years prior. Two cohorts of MERS-CoV survivors (31 unvaccinated, 38 COVID-19 vaccinated) were assessed for MERS-CoV IgG, memory CD4/CD8 T cells, and neutralizing antibodies against MERS-CoV and SARS-CoV-2 variants. MERS-CoV IgG levels and T cell responses were higher in the 1-5 vs 6-10 year postinfection groups. Vaccinated MERS-CoV survivors had significantly elevated MERS-CoV IgG and neutralization compared to unvaccinated. Both groups demonstrated cross-reactive neutralization of SARS-CoV-2 variants. MERS-CoV survivors vaccinated against SARS-CoV-2 had higher anti-MERS IgG, cellular immunity, and neutralization than unvaccinated survivors. MERS-CoV immune responses can persist for a decade. COVID-19 vaccination boosted humoral and cellular immunity in MERS-CoV survivors, suggesting the benefits of vaccination for this population. These findings have implications for pan-coronavirus vaccine development.

摘要

中东呼吸综合征（MERS）是一种由中东呼吸综合征冠状病毒（MERS-CoV）引起的呼吸道疾病。已有多起疫情报告，且该病毒与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）共同传播。对MERS-CoV的长期（>6年）细胞免疫和体液免疫反应及其对SARS-CoV-2及其变体的潜在交叉反应尚不清楚。我们全面调查了1至10年前从MERS-CoV感染中康复的个体中持久的MERS-CoV特异性细胞免疫和体液免疫，以及其对SARS-CoV-2及其变体的交叉反应。对两组MERS-CoV幸存者（31名未接种疫苗者、38名接种了新冠疫苗者）进行了评估，检测其针对MERS-CoV的IgG、记忆性CD4/CD8 T细胞以及针对MERS-CoV和SARS-CoV-2变体的中和抗体。感染后1至5年组的MERS-CoV IgG水平和T细胞反应高于6至10年组。与未接种疫苗的MERS-CoV幸存者相比，接种疫苗的幸存者的MERS-CoV IgG和中和能力显著提高。两组均表现出对SARS-CoV-2变体的交叉反应性中和作用。接种了SARS-CoV-2疫苗的MERS-CoV幸存者比未接种疫苗的幸存者具有更高的抗MERS IgG、细胞免疫和中和能力。MERS-CoV免疫反应可持续十年。新冠疫苗接种增强了MERS-CoV幸存者的体液免疫和细胞免疫，表明接种疫苗对该人群有益。这些发现对泛冠状病毒疫苗的研发具有启示意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e7/11740004/b5ed13e60c80/JMV-97-e70071-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e7/11740004/5063f03bd894/JMV-97-e70071-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e7/11740004/163ea96bf860/JMV-97-e70071-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e7/11740004/f5400ce131bc/JMV-97-e70071-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e7/11740004/a94414802ec4/JMV-97-e70071-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e7/11740004/8aa591169e95/JMV-97-e70071-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e7/11740004/b5ed13e60c80/JMV-97-e70071-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e7/11740004/5063f03bd894/JMV-97-e70071-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e7/11740004/163ea96bf860/JMV-97-e70071-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e7/11740004/f5400ce131bc/JMV-97-e70071-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e7/11740004/a94414802ec4/JMV-97-e70071-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e7/11740004/8aa591169e95/JMV-97-e70071-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e7/11740004/b5ed13e60c80/JMV-97-e70071-g001.jpg

相似文献

[1]
A 10 Year Long-Lived Cellular and Humoral MERS-CoV Immunity Cross-Recognizing the Wild-Type and Variants of SARS-CoV-2: A Potential One-Way MERS-CoV Cross-Protection Toward a Pan-Coronavirus Vaccine.

J Med Virol. 2025-1

[2]
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.

Front Immunol. 2021

[3]
mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-γ and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.

J Virol. 2025-3-18

[4]
Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.

J Virol. 2020-11-23

[5]
Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.

J Virol. 2024-9-17

[6]
Neutralizing Activity and T-Cell Responses Against Wild Type SARS-CoV-2 Virus and Omicron BA.5 Variant After Ancestral SARS-CoV-2 Vaccine Booster Dose in PLWH Receiving ART Based on CD4 T-Cell Count.

J Korean Med Sci. 2025-3-10

[7]
Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.

Microbiol Spectr. 2024-10-3

[8]
Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.

Front Immunol. 2025-1-22

[9]
Immune signature in vaccinated versus non-vaccinated aged people with COVID-19 pneumonia.

J Transl Med. 2024-8-12

[10]
Characterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort.

Pathogens. 2025-1-8

引用本文的文献

[1]
Recurrent MERS-CoV Transmission in Saudi Arabia- Renewed Lessons in Healthcare Preparedness and Surveillance.

J Epidemiol Glob Health. 2025-6-2

本文引用的文献

[1]
Distinct T cell polyfunctional profile in SARS-CoV-2 seronegative children associated with endemic human coronavirus cross-reactivity.

iScience. 2023-12-14

[2]
Assessment of Broadly Reactive Responses in Patients With MERS-CoV Infection and SARS-CoV-2 Vaccination.

JAMA Netw Open. 2023-6-1

[3]
Impact of MERS-CoV and SARS-CoV-2 Viral Infection on Immunoglobulin-IgG Cross-Reactivity.

Vaccines (Basel). 2023-2-26

[4]
Cross-Clade Memory Immunity in Adults Following SARS-CoV-1 Infection in 2003.

JAMA Netw Open. 2022-12-1

[5]
Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV.

EXCLI J. 2022-9-29

[6]
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses.

Nat Rev Immunol. 2023-3

[7]
Antibody Found in Mice Neutralizes SARS-CoV-2 and SARS-CoV-1.

JAMA. 2022-9-13

[8]
Middle East Respiratory Syndrome Coronavirus Infection Elicits Long-lasting Specific Antibody, T and B Cell Immune Responses in Recovered Individuals.

Clin Infect Dis. 2023-2-8

[9]
Severe Acute Respiratory Syndrome Coronavirus 2 Cross-Reactive B and T Cell Responses in Kidney Transplant Patients.

Transplant Proc. 2022

[10]
SARS-CoV-2 Antibody Response After ChAdOx1 nCoV-19 Vaccination in Persons With Previous SARS-CoV-1 Infection.

JAMA Intern Med. 2022-3-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索